Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer-associated thrombosis.

Bruce Furie1, Barbara C Furie

  • 1Division of Hemostasis and Thrombosis, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and the Department of Medicine, Harvard Medical School, Boston, MA 02215, USA. bfurie@bidmc.harvard.edu

Blood Cells, Molecules & Diseases
|February 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A coagulation defect arising from heterozygous premature termination of tissue factor.

The Journal of clinical investigation·2020
Same author

Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants.

Human mutation·2019
Same author

Identification of PDI Substrates by Mechanism-Based Kinetic Trapping.

Methods in molecular biology (Clifton, N.J.)·2019
Same author

Thiol isomerase ERp57 targets and modulates the lectin pathway of complement activation.

The Journal of biological chemistry·2019
Same author

Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer.

JCI insight·2019
Same author

Regulatory role of thiol isomerases in thrombus formation.

Expert review of hematology·2018

Cancer-associated thrombosis is a major complication with unclear molecular causes. Research suggests that tissue factor microparticles, found in cancer patients, may play a significant role in developing these dangerous blood clots.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Thrombosis is a significant complication in malignant diseases.
  • The precise molecular and cellular mechanisms driving cancer-associated thrombosis are not fully understood.
  • Existing hypotheses include tumor cell expression of tissue factor, chemotherapy-induced release, and unique tumor procoagulants.

Purpose of the Study:

  • To explore the potential role of microparticles in the development of cancer-associated thrombosis.
  • To investigate the presence and significance of tissue factor microparticles in cancer patients.

Main Methods:

  • Analysis of microparticle presence in cancer patients.
  • Assessment of tissue factor expression on microparticles.
  • Correlation of microparticle levels with thromboembolic complications.

Related Experiment Videos

Main Results:

  • Tissue factor microparticles were detected in a range of cancer patients.
  • These patients exhibited a high incidence of thromboembolic complications.
  • This suggests a link between microparticles and thrombosis risk in cancer.

Conclusions:

  • Microparticles, particularly those expressing tissue factor, are implicated in cancer-associated thrombosis.
  • Further research into microparticle-mediated pathways is warranted to understand and potentially prevent thrombosis in cancer patients.